Precision oncology is premised on identifying and drugging proteins and pathways that
drive tumorigenesis or are required for survival of tumor cells. Across diverse cancer types …

The most common driver gene mutation in patients with non‐small‐cell lung cancer
(NSCLC) is an epidermal growth factor receptor (EGFR) mutation. With the introduction of …

Recently, long noncoding RNAs (lncRNAs) have been shown to have important regulatory
roles in human cancer biology. The aim of this study was to evaluate the expression and …

Introduction The introduction of epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR-TKIs) has improved the outlook for patients with advanced non-small-cell lung …

Tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR) are becoming the
standard treatment option for patients with advanced non-small cell lung cancer (NSCLC) …

Host-directed therapeutics have the potential to combat the global tuberculosis pandemic.
We previously identified gefitinib, an inhibitor of EGFR, as a potential host-targeted …

MiR-198 is involved in tumorigenesis, migration, invasion, and metastasis of various
malignant cancers. However, the exact expression levels of miR-198 and the molecular …

OBJECTIVE: Lung cancer is the most frequent cancer in China and worldwide. Long
noncoding RNAs (lncRNAs) have been shown to play important regulatory roles in human …

Ginsenoside Rb2, a saponin from Panax ginseng, has been shown to have many functions.
However, the effect of ginsenoside Rb2 on the metastasis of colorectal cancer (CRC) …

The breakthrough of programmed cell death protein 1 (PD‐1) blockade therapy has
changed the clinical treatment of non‐small cell lung cancer (NSCLC) in the past few years …